Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines

Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of cetuximab response are known for HNSCC. Herein, we address the molecular mechanisms underlying cetuximab resistance in an in vitro mod...

Full description

Bibliographic Details
Main Authors: Izabela N. F. Gomes, Renato J. da Silva-Oliveira, Luciane Sussuchi da Silva, Olga Martinho, Adriane F. Evangelista, André van Helvoort Lengert, Letícia Ferro Leal, Viviane Aline Oliveira Silva, Stéphanie Piancenti dos Santos, Flávia Caroline Nascimento, André Lopes Carvalho, Rui Manuel Reis
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cells
Subjects:
EGFR
cetuximab
drug resistance
head and neck tumors
biomarkers
in vitro
Online Access:https://www.mdpi.com/2073-4409/11/1/154

Internet

https://www.mdpi.com/2073-4409/11/1/154

Similar Items